SPOTLIGHT -
Dr. Roussos Torres on the Importance of Preclinical Models in HER2+ Breast Cancer
Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.
Read More
Dr. Roussos Torres on the Potential for Immunotherapy in HER2+ Breast Cancer
Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
